Reuters logo
BRIEF-Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030
October 13, 2017 / 6:55 PM / in 7 days

BRIEF-Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030

Oct 13 (Reuters) - Orexigen Therapeutics Inc:

* Orexigen announces favorable decision from U.S. District Court in patent litigation, confirming exclusivity for Contrave through 2030

* Orexigen therapeutics - U.S. Court issued ruling in favor of Orexigen in litigation against Actavis Laboratories FL inc for three patents for Contrave​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below